Metabolic adverse effects include changes in weight, blood glucose and blood lipids. Risks vary substantially among second-generation antipsychotics. Olanzapine and clozapine are notable for substantial metabolic burdens, while other agents have different average profiles. Individual…Continue Reading
Medicines within the second generation differ in movement risks, prolactin effects, sedation, appetite, cardiovascular properties and metabolism. Risperidone can elevate prolactin and cause dose-related movement problems. Olanzapine has a broader profile associated with appetite and…Continue Reading
Examples include risperidone, olanzapine, quetiapine, clozapine and lurasidone. Some classifications also include D2 partial agonists within the second generation, while others describe them separately. The grouping is therefore useful historically but less precise than naming…Continue Reading
A receptor profile describes the targets a drug binds to and what it does after binding. Second-generation antipsychotics commonly affect D2 and 5-HT2A receptors, with varying actions at histamine, muscarinic and adrenergic receptors. Some also…Continue Reading
Second-generation antipsychotics can reduce psychotic symptoms, and some have additional evidence for particular mood-related conditions. Effects vary between medicines and individuals. Improvement may involve less distress or preoccupation even when an experience does not disappear…Continue Reading